Peoples Bank KS Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Peoples Bank KS acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 600 shares of the medical research company’s stock, valued at approximately $40,000.

A number of other large investors have also recently bought and sold shares of EW. Crewe Advisors LLC acquired a new position in Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences during the second quarter worth approximately $29,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $39,000. Finally, Rise Advisors LLC raised its position in shares of Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded up $0.12 during trading on Friday, reaching $65.49. The company had a trading volume of 5,579,069 shares, compared to its average volume of 4,560,924. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market capitalization of $39.46 billion, a PE ratio of 27.71, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13. The firm’s fifty day moving average is $66.58 and its 200 day moving average is $81.28.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the company posted $0.66 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Barclays reduced their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. The Goldman Sachs Group cut their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Citigroup decreased their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday. Sixteen investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average price target of $78.23.

Insiders Place Their Bets

In related news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,250 shares of company stock worth $1,218,138. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.